211 related articles for article (PubMed ID: 33940542)
21. Machine learning to refine prognostic and predictive nodal burden thresholds for post-operative radiotherapy in completely resected stage III-N2 non-small cell lung cancer.
Zarinshenas R; Ladbury C; McGee H; Raz D; Erhunmwunsee L; Pathak R; Glaser S; Salgia R; Williams T; Amini A
Radiother Oncol; 2022 Aug; 173():10-18. PubMed ID: 35618098
[TBL] [Abstract][Full Text] [Related]
22. Postoperative radiotherapy for patients with completely resected pathologic n2 non-small-cell lung cancer: a retrospective analysis.
Mantovani C; Levra NG; Filippi AR; Novello S; Buffoni L; Ragona R; Ricardi U
Clin Lung Cancer; 2013 Mar; 14(2):194-9. PubMed ID: 22885347
[TBL] [Abstract][Full Text] [Related]
23. The lymph node status and histologic subtypes influenced the effect of postoperative radiotherapy on patients with N2 positive IIIA non-small cell lung cancer.
Yuan C; Tao X; Zheng D; Pan Y; Ye T; Hu H; Xiang J; Zhang Y; Chen H; Sun Y
J Surg Oncol; 2019 Mar; 119(3):379-387. PubMed ID: 30536966
[TBL] [Abstract][Full Text] [Related]
24. Benefits of postoperative radiotherapy in multimodality treatment of resected small-cell lung cancer with lymph node metastasis.
Liu WS; Zhao LJ; Wang S; Gong LL; Liu ZY; Yuan ZY; Wang P
Eur J Surg Oncol; 2014 Sep; 40(9):1156-62. PubMed ID: 24655801
[TBL] [Abstract][Full Text] [Related]
25. Postoperative Radiotherapy for Resected Stage IIIA-N2 Non-small-cell Lung Cancer: A Population-Based Time-Trend Study.
Zeng WQ; Feng W; Xie L; Zhang CC; Yu W; Cai XW; Fu XL
Lung; 2019 Dec; 197(6):741-751. PubMed ID: 31705271
[TBL] [Abstract][Full Text] [Related]
26. Preoperative CT-based radiomic prognostic index to predict the benefit of postoperative radiotherapy in patients with non-small cell lung cancer: a multicenter study.
Ma Z; Men Y; Liu Y; Bao Y; Liu Q; Yang X; Wang J; Deng L; Zhai Y; Bi N; Wang L; Hui Z
Cancer Imaging; 2024 May; 24(1):61. PubMed ID: 38741207
[TBL] [Abstract][Full Text] [Related]
27. Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: focusing on an effect of the number of mediastinal lymph node stations involved.
Matsuguma H; Nakahara R; Ishikawa Y; Suzuki H; Inoue K; Katano S; Yokoi K
Interact Cardiovasc Thorac Surg; 2008 Aug; 7(4):573-7. PubMed ID: 18413349
[TBL] [Abstract][Full Text] [Related]
28. Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data.
Le Péchoux C
Oncologist; 2011; 16(5):672-81. PubMed ID: 21378080
[TBL] [Abstract][Full Text] [Related]
29. Association between clinicopathological factors and postoperative radiotherapy in patients with completely resected pathological N2 non-small cell lung cancer.
Xu Y; Li J; Wang J; Hu X; Ma H; Li P; Zheng X; Chen M
Oncol Lett; 2018 Feb; 15(2):2641-2650. PubMed ID: 29434986
[TBL] [Abstract][Full Text] [Related]
30. [Factors influencing survival and recurrence and potential significance of postoperative radiotherapy and adjuvant chemotherapy for stage ⅢA-N2 non-small cell lung cancer].
Han W; Song YZ; He M; Li J; Zhang R; Qiao XY
Zhonghua Zhong Liu Za Zhi; 2016 Nov; 38(11):861-867. PubMed ID: 27998447
[No Abstract] [Full Text] [Related]
31. Impact of pathological nodal staging and tumour differentiation on survival and postoperative radiotherapy in completely resected stage IIIA Non-small-cell lung cancer.
Ku HY; Lin SM; Wang CL; Lo YC; Chang CS; Chang GC; Ch'ang HJ; Liu TW
Lung Cancer; 2023 Oct; 184():107357. PubMed ID: 37666022
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
[TBL] [Abstract][Full Text] [Related]
33. Real world practice of postoperative radiotherapy for patients with completely resected pIIIA-N2 non-small cell lung cancer: a national survey of radiation oncologists in China.
Zhou S; Zhai Y; Zhao K; Men Y; Meng X; Hui Z
Radiat Oncol; 2023 Jan; 18(1):17. PubMed ID: 36698150
[TBL] [Abstract][Full Text] [Related]
34. The impact of postoperative radiotherapy on the survival of patients with stage III non-small cell lung cancer: A CONSORT-compliant analysis using the SEER database.
Wu K; Peng W; Shuai Z; Peng X; Liu H; Zhang S
Medicine (Baltimore); 2023 Jun; 102(24):e34015. PubMed ID: 37327271
[TBL] [Abstract][Full Text] [Related]
35. Patients with Lower Positive Lymph Nodes Ratio May Benefit from Preoperative Radiotherapy in Stage III Non-Small Cell Lung Cancer.
Wang R; Shang S; Huang X; Nie Y; Wang F; Yu J; Chen D
Technol Cancer Res Treat; 2023; 22():15330338231173498. PubMed ID: 37157831
[TBL] [Abstract][Full Text] [Related]
36. Outcome and prognostic factors of postoperative radiation therapy (PORT) after incomplete resection of non-small cell lung cancer (NSCLC).
Rieber J; Deeg A; Ullrich E; Foerster R; Bischof M; Warth A; Schnabel PA; Muley T; Kappes J; Heussel CP; Welzel T; Thomas M; Steins M; Dienemann H; Debus J; Hoffmann H; Rieken S
Lung Cancer; 2016 Jan; 91():41-7. PubMed ID: 26711933
[TBL] [Abstract][Full Text] [Related]
37. The Role of Postoperative Radiation Therapy for pN2 Non-small-cell Lung Cancer.
Mankuzhy NP; Almahariq MF; Siddiqui ZA; Thompson AB; Grills IS; Guerrero TM; Lee KC; Stevens CW; Quinn TJ
Clin Lung Cancer; 2021 Jan; 22(1):e5-e17. PubMed ID: 32873482
[TBL] [Abstract][Full Text] [Related]
38. Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non-Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database.
Herskovic A; Mauer E; Christos P; Nagar H
J Thorac Oncol; 2017 Feb; 12(2):302-313. PubMed ID: 27746190
[TBL] [Abstract][Full Text] [Related]
39. Male patients with resected IIIA-N2 non-small-cell lung cancer may benefit from postoperative radiotherapy: a population-based survival analysis.
Kou P; Wang H; Lin J; Zhang Y; Yu J
Future Oncol; 2018 Oct; 14(23):2371-2381. PubMed ID: 29807451
[TBL] [Abstract][Full Text] [Related]
40. A biomarker-based prediction model for risk of locoregional recurrence in pathologic stage IIIA-N2 non-small cell lung cancer.
Jiang G; Huang J; Cui T; Lin X; Lin G
Int J Clin Exp Pathol; 2020; 13(12):3060-3082. PubMed ID: 33425107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
